RT Journal Article
SR Electronic
T1 Antiepileptic Drug Development Program
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 293
OP 305
VO 51
IS 2
A1 Porter, Roger J.
A1 Cereghino, James J.
A1 Gladding, Gill D.
A1 Hessie, Bettiejean
A1 Kupferberg, Harvey J.
A1 Scoville, Barrett
A1 White, Billy G.
YR 1984
UL http://www.ccjm.org/content/51/2/293.abstract
AB The modern era of antiepileptic drug therapy began with the use of phenobarbital in 1912. In the years thereafter, many new drugs were introduced, including other barbiturates, hydantoins, succinimides, and oxazolidinediones. Then, for various reasons, the marketing of new antiepileptic drugs was dramatically curtailed. To help reverse this trend, the Epilepsy Branch of the National Institute of Neurological and Communicative Disorders and Stroke sponsored clinical trials of drugs which had already been marketed abroad, resulting in the distribution of clonazepam, carbamazepine, and valproic acid in the U.S. These trials were followed by the establishment of the Antiepileptic Drug Development Program, which encompasses both the preclinical and clinical elements of drug development, including the Anticonvulsant Screening Project, the Toxicology Project, and support for controlled clinical trials.